Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AP Pharma Strengthens Board Of Directors
Mr Davis was the chief executive officer for Neurogen Corporation, which was recently acquired by Ligand Pharmaceuticals. His appointment brings the number of AP Pharma board members to
Mr Davis was the chief executive officer for Neurogen Corporation, which was recently acquired by Ligand Pharmaceuticals. His appointment brings the number of AP Pharma board members to
Additionally, the board has also appointed John Lomoro, the company’s chief financial officer, as acting CEO. Reportedly, following the resignation of Juliet Singh from her post as president
The partnership is expected to allow MTS and Cool Logistics to expand their operations globally, as well as to offer a complete range of products to all clients.
The Acquisition was finalised after the approval by Asterand’s shareholders at an extraordinary general meeting held on February 18, 2010, where all resolutions put to shareholders were duly
The study investigated the use of GM-CSF (granulocyte/macrophage colony-stimulating factor) as an adjuvant with the DNA prime for the GeoVax DNA/MVA vaccine for prevention of HIV/AIDS. The National
StromaCel is the fifth subsidiary of Proteonomix, whose operating subsidiary is National Stem Cell. Its subsidiary is The Sperm Bank of New York, which is engaged in reproductive
According to the terms of the deal, Natac, through its subsidiary Natac Research, has consented to offer the services of senior research scientists and the associated laboratory facilities,
Genoptix has obtained exclusive commercial laboratory rights in the US to develop and perform three solid tumor assays using HistoRx’s proprietary technology for analysis of fluorescent immunohistochemistry (fIHC),
Earlier, in October 2009, the division of reproductive and urologic products at FDA has issued a complete response letter for the biologic license application (BLA) for Prolia in
The MAA was withdrawn following communication from the Committee for Medicinal Products for Human Use (CHMP) of the EMA citing a major objection. The major objection noted that